Incannex Healthcare (ASX:IHL) - Managing Director and CEO, Joel Latham
Managing Director and CEO, Joel Latham
Source: Joel Latham/LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Incannex Healthcare (IHL) announces positive findings from a preclinical study trialling its IHL-216A drug in rodent models
  • The study compared IHL-216A to CBD and isoflurane in a study model developed with the US NFL to mimic the type of brain injury that occurs in sports-related concussions
  • IHL-216A restored spatial memory after 24 hours in rodent models, while rats treated with CBD alone experienced only a partially restored spatial memory
  • Incannex says the results further support the benefits of its drug, and it is expediting a pre-Investigational New Drug (IND) meeting with the US FDA later this year
  • IHL shares are trading 7.89 per cent lower at 35 cents

Incannex Healthcare (IHL) has announced some positive findings from a preclinical study trialling its IHL-216A drug in head injuries.

The study compared IHL-216A to its component drug, cannabidiol (CBD), and isoflurane, using six groups of 24 Sprague Dawley rats.

The study model was developed in collaboration with the US National Football League (NFL) to represent the type of brain injury that can occur in sports-related concussions.

Concussions experienced by NFL players were scaled to the rodent subjects to mimic the collision mechanics.

IHL-216A was observed to have a strong neuroprotective effect in that it restored spatial memory after 24 hours in injured rodent models, while those that only received the vehicle as treatment didn’t have restored spatial memory.

Rats who were treated with CBD alone experienced only a partially restored spatial memory, further supporting the benefits of Incannex Healthcare’s novel drug combination compared to CBD alone.

IHL Chief Scientific Officer Dr Mark Bleackley said it was “exciting” that Incannex had observed a neuroprotective effect for IHL-216A.

“Combining the results from our two animal studies indicates that IHL-216A has the potential to be effective at reducing the effects of traumatic brain injuries across the spectrum of injury severity,” Dr Bleackley said.

Due to the positive preclinical results, the healthcare stock has begun preparations of a pre-Investigational New Drug (IND) meeting package for IHL-216A.

The company is targeting a pre-IND meeting with the US Food and Drug Administration (FDA) in the September 2022 quarter. The meeting will discuss Incannex’s plan to conduct a clinical trial for a new drug application and marketing approval.

IHL was down 7.89 per cent to trade at 35 cents at 11:10 am AEST.

IHL by the numbers
More From The Market Herald
Countplus (ASX:CUP) - Incoming CEO, Hugh Humphrey

" Hugh Humphrey appointed CEO of Countplus (ASX:CUP)

Investment services company CountPlus (ASX:CUP) has appointed Hugh Humphrey as the company's CEO, effective July 1.

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…